Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | IDH2 | P48735 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5341690 | 0.79 | USP30 (0.48) | USP30SYKGPR119MAPK14ADORA2A | |
| SCHEMBL5914088 | 0.77 | USP30 (0.46) | USP30SYKGPR119MAPK14ADORA2A | |
| SCHEMBL5913836 | 0.76 | ALDH1A1 (0.48) | USP30SYKGPR119MAPK14ADORA2A | |
| SCHEMBL5263546 | 0.76 | USP30 (0.44) | USP30GPR119MAPK14ADORA2AIDH1 | |
| SCHEMBL5948116 | 0.75 | USP30 (0.44) | USP30SYKGPR119MAPK14ADORA2A | |
| SCHEMBL5259529 | 0.73 | ACACB (0.36) | MAPK14BRD4 | |
| SCHEMBL3650816 | 0.72 | HDAC8 (0.52) | USP30SYKADORA2AIDH1IDH2 | |
| SCHEMBL3775260 | 0.72 | USP30 (0.67) | USP30GPR119ALDH1A1 | |
| SCHEMBL5913810 | 0.71 | MAPK8 (0.48) | USP30MAPK14ALDH1A1 | |
| SCHEMBL14190733 | 0.71 | ALDH1A1 (0.55) | USP30SYKGPR119ADORA2AIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-12-29 | — | — | US | claimed |
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, IAPP, MAPT | USP30 3642/4885SYK 767/4885GPR119 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.